FDA likely to approve Pfizer-BioNTech vaccine, research head says
Andrew Baum, global head of health care research at Citi, says the U.S. Food and Drug Administration (FDA) is very likely to approve the Pfizer-BioNTech vaccine soon.
Andrew Baum, global head of health care research at Citi, says the U.S. Food and Drug Administration (FDA) is very likely to approve the Pfizer-BioNTech vaccine soon.
